Immunohistochemistry in prostate pathology

1.   Gatalica Z, Norris BA, Kovatich AJ. Immunohistochemical localization of prostate-specific antigen in ductal epithelium of male breast. Potential diagnostic pitfall in patients with gynecomastia. Appl Immunohistochem Mol Morphol 2000; 8(2): 158-161.

2.   van Krieken JH. Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry. Am JSurg Pathol 1993; 17(4): 410-414.

3.   Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology 2005; 47(1):1-16.

4.   Bonk S, Kluth M, Hube-Magg C, et al. Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. Oncotarget 2019; 10(52): 5439-5453.

5.   Varma M, Morgan M, Jasani B, Tamboli P, Amin MB. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: Implications for diagnostic prostatic pathology. Am J Clin Pathol 2002; 118(2): 202-207.

6.   Barresi V, Ieni A, Cardia R, et al. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors. APMIS 2016; 124(3): 188-193.

7.   Gurel B, Ali TZ, Montgomery EA, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol 2010;34(8): 1097-1105.

8.   Kristiansen I, Stephan C, Jung K, et al. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA. Int J Mol Sci 2017;18(6): 1151.

9.   Sheridan T, Herawi M, Epstein JI, Illei PB. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol 2007; 31(9):1351-1355.

10. Mai KT, Commons AS, Perkins DG, Yazdi HM, Collins JP. Absence of serum prostate-specific antigen and loss of tissue immunoreactive prostatic markers in advanced prostatic adenocarcinoma after hormonal therapy: a report of two cases. Hum Pathol 1996; 27(12): 1377-1381.

11. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004; 64(24): 9209-9216.

12. Xu J, Kalos M, Stolk JA, et al. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res 2001; 61(4): 1563-1568.

13. Yin M, Dhir R, Parwani AV. Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma. Diagn Pathol 2007; 2: 41.

14. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007; 50(4): 472-483.

15. Marchal C, Redondo M, Padilla M, et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Histol Histopathol 2004; 19(3): 715-718.

16. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007; 38(5): 696-701.

17. Wang W, Tavora F, Sharma R, Eisenberger M, Netto GJ. PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma. Urol Oncol 2009; 27(5): 525-528.

18. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res1997; 3(1):81-85.

19. Lane Z, Hansel DE, Epstein JI. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Am J Surg Pathol 2008; 32(9): 1322-6.

20. Jobsis AC, De Vries GP, Meijer AE, Ploem JS. The immunohistochemical detection of prostatic acid phosphatase: its possibilities and limitations in tumour histochemistry. Histochem J 1981; 13(6): 961-973.

21. Haines AM, Larkin SE, Richardson AP, Stirling RW, Heyderman E. A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer 1989; 60(6): 887-892.

22. Kimura N, Sasano N. Prostate-specific acid phosphatase in carcinoid tumors. Virchows Arch A Pathol Anat Histopathol 1986; 410(3): 247-251.

23. Elgamal AA, Ectors NL, Sunardhi-Widyaputra S, Van Poppel HP, Van Damme BJ, Baert LV. Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. J Urol 1996; 156(2 Pt 1): 464-468.

24. Graddis TJ, McMahan CJ, Tamman J, Page KJ, Trager JB. Prostatic acid phosphatase expression in human tissues. Int J Clin Exp Pathol 2011; 4(3): 295-306.

25. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002; 117(3): 471-477.

26. Varma M, Berney DM, Jasani B, Rhodes A. Technical variations in prostatic immunohistochemistry: need for standardisation and stringent quality assurance in PSA and PSAP immunostaining. J Clin Pathol 2004; 57(7): 687-690.

27. Huang H, Guma SR, Melamed J, Zhou M, Lee P, Deng FM. NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens. Am J Clin Exp Urol 2018; 6(5):182-188.

28. Varinot J, Cussenot O, Roupret M, et al. HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. Virchows Arch 2013; 463(6): 803-809.

29. Varinot J, Furudoi A, Drouin S, et al. HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin. Virchows Arch 2016; 468(5): 619-622.

30. Barresi V, Ieni A, Reggiani Bonetti L, Tuccari G. HOXB13 expression in metastatic prostate cancer. Virchows Arch 2016; 469(1): 119-120.

31. Bellizzi AM. An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin. Adv Anat Pathol 2020; 27(3): 114-163.

32. Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 1989; 13(5): 389-396.

33. Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol 2005; 22(1): 88-104.

34. Al Diffalha S, Shaar M, Barkan GA, Wojcik EM, Picken MM, Pambuccian SE. Immunohistochemistry in the workup of prostate biopsies: Frequency, variation and appropriateness of use among pathologists practicing at an academic center. Ann Diagn Pathol 2017; 27: 34-42.

35. Abrahams NA, Ormsby AH, Brainard J. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies. Histopathology  2002; 41(1): 35-41.

36. Brustmann H. p40 as a Basal Cell Marker in the Diagnosis of Prostate Glandular Proliferations: A Comparative Immunohistochemical Study with 34betaE12. Pathol Res Int 2015; 2015: 897927.

37. Kuroda N, Katto K, Tamura M, et al. Immunohistochemical application of D2-40 as basal cell marker in evaluating atypical small acinar proliferation of initial routine prostatic needle biopsy materials. Med Mol Morphol 2010; 43(3): 165-169.

38. Paner GP, Luthringer DJ, Amin MB. Best practice in diagnostic immunohistochemistry: prostate carcinoma and its mimics in needle core biopsies. Arch Pathol Lab Med 2008; 132(9): 1388-1396.

39. Tan HL, Haffner MC, Esopi DM, et al. Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. Mod Pathol 2015; 28(3): 446-456.

40. Herawi M, Parwani AV, Irie J, Epstein JI. Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion. Am J Surg Pathol 2005; 29(7): 874-880.

41. Beach R, Gown AM, De Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 2002; 26(12): 1588-1596.

42. Shidham VB, Lindholm PF, Kajdacsy-Balla A, Basir Z, George V, Garcia FU. Prostate-specific antigen expression and lipochrome pigment granules in the differential diagnosis of prostatic adenocarcinoma versus seminal vesicle-ejaculatory duct epithelium. Arch Pathol Lab Med 1999; 123(11): 1093-1097.

43. Ortiz-Rey JA, Juaneda-Benavides L, Peteiro-Cancelo A, de Maria CG, Tejado BS, Tardio-Baiges A. Another application of PAX8: to confirm the presence of seminal vesicle epithelium in prostate needle biopsies. Appl Immunohistochem Mol Morphol 2015; 23(2): 161-162.

44. Tong GX, Memeo L, Colarossi C, et al. PAX8 and PAX2 immunostaining facilitates the diagnosis of primary epithelial neoplasms of the male genital tract. Am J Surg Pathol 2011; 35(10): 1473-1483.

45. Pivovarčíková K, Švajdler M, Hes O. Využití imunohistochemie při diagnostice lézí vývodného močového traktu. Cesk Slov Patol 2020, 140-152.

46. Allan CH, Epstein JI. Nephrogenic adenoma of the prostatic urethra: a mimicker of prostate adenocarcinoma. Am J Surg Pathol 2001; 25(6): 802-808.

47. Elgamal AA, Van de Voorde W, Van Poppel H, Lauweryns J, Baert L. Immunohistochemical localization of prostate-specific markers within the accessory male sex glands of Cowper, Littre, and Morgagni. Urology 1994; 44(1): 84-90.

48. Cina SJ, Silberman MA, Kahane H, Epstein JI. Diagnosis of Cowper’s glands on prostate needle biopsy. Am J Surg Pathol 1997; 21(5): 550-555.

49. Saboorian MH, Huffman H, Ashfaq R, Ayala AG, Ro JY. Distinguishing Cowper’s glands from neoplastic and pseudoneoplastic lesions of prostate: immunohistochemical and ultrastructural studies. Am J Surg Pathol 1997; 21(9): 1069-1074.

50. Srigley JR. Benign mimickers of prostatic adenocarcinoma. Mod Pathol 2004; 17(3): 328-348.

51. Bostwick DG, Qian J, Ma J, Muir TE. Mesonephric remnants of the prostate: incidence and histologic spectrum. Mod Pathol 2003; 16(7): 630-635.

52. Chen YB, Fine SW, Epstein JI. Mesonephric remnant hyperplasia involving prostate and periprostatic tissue: findings at radical prostatectomy. Am J Surg Pathol 2011; 35(7): 1054-1061.

53. Bostwick DG, Srigley J, Grignon D, et al. Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol 1993; 24(8): 819-832.

54. Yang XJ, Wu CL, Woda BA, et al. Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 2002; 26(7): 921-925.

55. Gordetsky J, Epstein JI. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall. Am J Surg Pathol 2014; 38(7): 941-945.

56. Schelling LA, Williamson SR, Zhang S, et al. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum Pathol 2013; 44(10): 2227-2233.

57. Bezerra SM, Lotan TL, Faraj SF, et al. GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin. Hum Pathol 2014; 45(8): 1682-1687.

58. Guo CC, Dancer JY, Wang Y, Aparicio A, et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 2011; 42(1): 11-17.

59. Lotan TL, Gupta NS, Wang W, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011; 24(6): 820-828.

60. Williamson SR, Zhang S, Yao JL, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol 2011; 24(8): 1120-1127.

61. Erdem GU, Ozdemir NY, Demirci NS, Sahin S, Bozkaya Y, Zengin N. Small cell carcinoma of the urinary bladder: changing trends in the current literature. Curr Med Research Opin 2016; 32(6): 1013-1021.